Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 38, 2008, Pages 14567-14572

  Hammarlund, Erika ^a   Dasgupta, Anindya ^a   Pinilla, Clemencia ^b   Norori, Patricia ^b   Früh, Klaus ^a   Slifka, Mark K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Immune evasion; Orthopoxvirus; T cell immunity

Indexed keywords

CYTOKINE; T LYMPHOCYTE RECEPTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; MONKEYPOX VIRUS; PRIORITY JOURNAL; VACCINIA VIRUS;

ANTIGEN PRESENTATION; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION; GENES, MHC CLASS I; GENES, MHC CLASS II; HERPESVIRUS 4, HUMAN; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MONKEYPOX; MONKEYPOX VIRUS; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

COWPOX VIRUS; MONKEYPOX VIRUS; MOROCCAN PEPPER VIRUS; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 55749084924     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0800589105     Document Type: Article

References (50)

1. Henderson DA (1999) The looming threat of bioterrorism. Science 283:1279-1282.
2. O'Toole T, Mair M, Inglesby TV (2002) Shining light on "Dark Winter." Clin Infect Dis 34:972-983.
3. Smith GL, McFadden G (2002) Smallpox: Anything to declare? Nat Rev Immunol 2:521-527.
4. Slifka MK (2005) The future of smallpox vaccination: Is MVA the key? Med Immunol 4:2.
5. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M (1987) Human monkeypox: Clinical features of 282 patients. J Infect Dis 156:293-298.
6. Jezek Z, Grab B, Paluku KM, Szczeniowski MV (1988) Human monkeypox: Disease pattern, incidence and attack rates in a rural area of northern Zaire. Trop Geogr Med 40:73-83.
7. Hutin YJ, et al. (2001) Outbreak of human monkeypox. Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 7:434-438.
8. Meyer H, et al. (2002) Outbreaks of disease suspected of being due to human monkeypox virus infection in the democratic republic of congo in 2001. J Clin Microbiol 40:2919-2921.
9. Reed KD, et al. (2004) The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350:342-350.
10. Hammarlund E, et al. (2005) Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypoxNat Med 11:1005-1011.
11. Rimoin AW, et al. (2007) Endemic human monkeypox, Democratic Republic of Congo, 2001-2004. Emerg Infect Dis 13:934-937.
12. Jezek Z, et al. (1986) Four generations of probable person-to-person transmission of human monkeypox. Am J Epidemiol 123:1004-1012.
13. Fine PE, Jezek Z, Grab B, Dixon H (1988) The transmission potential of monkeypox virus in human populations. Int J Epidemiol 17:643-650.
14. Fleischauer AT, et al. (2005) Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis 40:689-694.
15. Cho CT, Wenner HA (1973) Monkeypox virus. Bacteriol Rev 37:1-18.
16. Jezek Z, Fenner F (1988) in Monographs in Virology, ed Melnick JL (Karger, Basel), Vol 17, pp 140.
17. Earl PL, et al. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
18. Edghill-Smith Y, et al. (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11:740-747.
19. Cummings JF, et al. (2004) Lack of vaccinia viremia after smallpox vaccination. Clin Infect Dis 38:456-458.
20. Downie AW, McCarthy K, MacDonald A, MacCallum FO, Macrae AD (1953) Virus and virus antigen in the blood of smallpox patients. Their significance in early diagnosis and prognosis. Lancet 265:164-166.
21. Jahrling PB, et al. (2004) Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA 101:15196-15200.
22. Wenner HA, Cho CT, Bolano C, Kamitsuka PS (1969) Monkey pox IV modification of disease pattern by antilymphocytic sera. J Infect Dis 120:318-331.
23. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L (2001) The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 81:1581-1600.
24. Verlinde JD, Van Tongeren HA (1952) Isolation of smallpox virus from the nasopharynx of patients with variola sine eruptione. Antonie Van Leeuwenhoek 18:109-112.
25. Bras G (1952) The morbid anatomy of smallpox. Doc Med Geogr Trop 4:303-351.
26. Kempe CH, Dekking F, Saint Vincent L, Rao AR, Downie AW (1969) Conjunctivitis and subclinical infection in smallpox. J Hyg (London) 67:631-636.
27. Heiner GG, et al. (1971) A study of inapparent infection in smallpox. Am J Epidemiol 94:252-268.
28. Sarkar JK, Mitra AC, Mukherjee MK, De SK (1972) Variola virus in the throat of healthy contacts of small-pox cases. Bull Calcutta Sch Trop Med 20:61-62.
29. Sarkar JK, Mitra AC, Mukherjee MK (1973) Serial isolation of variola virus in the throat of household contacts of smallpox cases. Bull Calcutta Sch Trop Med 21:21-22.
30. Sarkar JK, Mitra AC, Mukherjee MK (1974) Duration of virus excretion in the throat of asymptomatic household contacts of smallpox patients. Indian J Med Res 62:1800-1803.
31. Arita I, Henderson DA (1968) Smallpox and monkeypox in non-human primates. Bull World Health Organ 39:277-283.
32. Gispen R, Brand-Saathof B (1972) "White" poxvirus strains from monkeys. Bull World Health Organ 46:585-592.
33. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL (2000) Viral subversion of the immune system. Annu Rev Immunol 18:861-926.
34. Cornell CT, Kiosses WB, Harkins S, Whitton JL (2007) Coxsackievirus B3 proteins directionally complement each other to down-regulate surface major histocompatibility complex class IJ Virol 81:6785-6797.
35. Fruh K, Bartee E, Gouveia K, Mansouri M (2002) Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res 88:55-69.
36. Hill A, et al. (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415.
37. Fruh K, et al. (1995) A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415-418.
38. Pande NT, Powers C, Ahn K, Fruh K (2005) Rhesus cytomegalovirus contains functional homologues of US2, US3, US6, and US11. J Virol 79:5786-5798.
39. Seet BT, et al. (2003) Poxviruses and immune evasion. Annu Rev Immunol 21:377-423.
40. Dasgupta A, Hammarlund E, Slifka MK, Fruh K (2007) Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J Immunol 178:1654-1661.
41. Byun M, Wang X, Pak M, Hansen TH, Yokoyama WM (2007) Cowpox virus exploits the endoplasmic reticulum retention pathway to inhibit MHC class I transport to the cell surface. Cell Host Microbe 2:306-315.
42. Johnston JB, Rahman MM, McFadden G (2007) Strategies that modulate inflammasomes: Insights from host-pathogen interactions. Semin Immunopathol 29:261-274.
43. Amati L, et al. (2006) Taking advantage of viral immune evasion: Virus-derived proteins represent novel biopharmaceuticals. Curr Med Chem 13:325-333.
44. Oseroff C, et al. (2005) HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 102:13980-13985.
45. Hammarlund E, et al. (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9:1131-1137.
46. Lee DH, Goldberg AL (1998) Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol 8:397-403.
47. Andersson M, Paabo S, Nilsson T, Peterson PA (1985) Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 43:215-222.
48. Tomazin R, et al. (1999) Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med 5:1039-1043
49. Slifka MK (2004) Immunological memory to viral infection. Curr Opin Immunol 16:443-450.
50. Couzi G, Kircher JP (1941) Immunotherapie de la Variole. Bulletin de l'Institut d'hygiene du Maroc 1:59-68.